Clinical Trial Update: A Multicenter Real-world Clinical Study on the Efficacy and Safety of Ensartinib As Neoadjuvant Treatment for Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer (NSCLC) Patients.

View source ↗

Summary

The document describes a multicenter real-world study evaluating ensartinib as neoadjuvant therapy for ALK-positive non-small cell lung cancer; recruitment has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ensartinib (Ensartinib)

Snippet

Sponsor: Harbin Medical University | Conditions: ALK Positive, Ensartinib | Status: NOT_YET_RECRUITING